
Oct 27, 2021
Biomica & Rambam Health Care Campus Sign Agreement for Clinical Trial of Biomica’s Microbiome-Based Immuno-Oncology Drug
Biomica expects to initiate first-in-human, proof-of-concept study later this year
Biomica expects to initiate first-in-human, proof-of-concept study later this year
Today announced that Dr. Elran Haber, Chief Executive Officer of Biomica, will present at the Jefferies Microbiome-Based Therapeutics Summit being held on Thursday, April 22, 2021.
Biomica’s live biotherapeutic drug candidate, BMC128, significantly increased anti-tumor activity in combination with Immune Checkpoint Inhibitors in Melanoma. First-in-human, proof of concept study expected later this year